Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FURESTEM-OA is an allogeneic cell therapy developed by Kangstem Biotech for the treatment of knee osteoarthritis. It consists of mesenchymal stem cells (MSCs) derived from human umbilical cord blood, isolated and expanded using the company's proprietary SEL-STEM technology. The therapy is designed to be administered via a single intra-articular injection into the knee joint. Once administered, the MSCs exert therapeutic effects through paracrine signaling, secreting various anti-inflammatory cytokines and growth factors that modulate the immune environment within the joint and promote the regeneration of damaged cartilage. FURESTEM-OA aims to alleviate pain and improve joint function, potentially offering a disease-modifying alternative to conventional symptomatic treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FURESTEM-OA.